Progressive Supranuclear Palsy (PSP) is a neurodegenerative disorder that is characterized by progressive impairment of balance, movement, vision, and cognition. The cause of PSP is still unknown, and there is currently no cure for the disease. However, there are treatments available that can help manage the symptoms and slow down the progression of the disease. One such treatment option is the use of benzodiazepine derivatives, which are commonly prescribed to patients with PSP for insomnia and anxiety.
A recent post hoc analysis of a phase II/III clinical trial shed light on the impact of benzodiazepine derivatives on the progression of PSP. The study found that individuals who were prescribed benzodiazepine derivatives had a faster decline in PSP Rating Scale (PSPRS) scores compared to those who did not take benzodiazepines. The analysis included 305 participants who were assessed over a span of 52 weeks.
Deterioration in PSPRS Scores
The study revealed that only benzodiazepine derivatives, including lorazepam, clonazepam, alprazolam, and diazepam, were associated with a more rapid worsening of PSPRS scores. This deterioration was statistically significant (P<0.001) and occurred at week 39 and week 52 of the trial. Participants who took benzodiazepines experienced a mean worsening of 17.1 PSPRS points per year, compared to 9.9 points per year for those not taking benzodiazepines.
Interestingly, benzodiazepine-related drugs such as zolpidem, zopiclone, and eszopiclone were not found to be associated with worsening PSPRS scores. This suggests that there may be other modifiable factors that can influence the progression of PSP. The study authors also noted that the duration and dose of benzodiazepine exposure did not seem to be related to the rate of change in PSPRS scores, possibly due to the limited sample size.
The findings of this study have important implications for the treatment of PSP. Benzodiazepines, which are commonly prescribed for insomnia and anxiety in PSP patients, may actually contribute to faster disease progression. This highlights the need for healthcare providers to carefully consider the potential risks and benefits of prescribing benzodiazepine derivatives to patients with PSP.
It is important to note that this study does not establish a causal relationship between benzodiazepines and worsening disease. The analysis was limited by confounding variables and the retrospective nature of the study design. The researchers also acknowledged that the infrequent study visits prevented the evaluation of the acute symptomatic effects of benzodiazepines.
The use of benzodiazepine derivatives in individuals with PSP appears to be associated with a faster decline in PSPRS scores. Healthcare providers should exercise caution when prescribing these medications to patients with PSP, taking into consideration the potential risks and benefits. Further research is needed to fully understand the impact of benzodiazepines on the progression of PSP and to explore other modifiable factors that may influence disease progression. With a better understanding of the factors that affect PSP progression, more effective treatment strategies can be developed to improve the quality of life for individuals living with this debilitating disorder.
Leave a Reply